Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. more
Time Frame | MIRM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.12% | -3.72% | -0.05% |
1-Month Return | 2.34% | -1.85% | 2.75% |
3-Month Return | 4.87% | -11.4% | 7.4% |
6-Month Return | 28.45% | -4.41% | 10.47% |
1-Year Return | 44.26% | 4.13% | 27.57% |
3-Year Return | 183.17% | 0.3% | 29.56% |
5-Year Return | 145.31% | 36.62% | 89.3% |
10-Year Return | 220.89% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 11.00M | 19.14M | 77.06M | 186.37M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.9,"profit":true},{"date":"2021-12-31","value":10.27,"profit":true},{"date":"2022-12-31","value":41.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 324.00K | 623.00K | 1.90M | 12.37M | 47.04M | [{"date":"2019-12-31","value":0.69,"profit":true},{"date":"2020-12-31","value":1.32,"profit":true},{"date":"2021-12-31","value":4.05,"profit":true},{"date":"2022-12-31","value":26.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (324.00K) | (623.00K) | 17.23M | 64.69M | 139.34M | [{"date":"2019-12-31","value":-0.23,"profit":false},{"date":"2020-12-31","value":-0.45,"profit":false},{"date":"2021-12-31","value":12.37,"profit":true},{"date":"2022-12-31","value":46.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (5.66%) | 90.06% | 83.94% | 74.76% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-6.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.21,"profit":true},{"date":"2023-12-31","value":83.02,"profit":true}] |
Operating Expenses | 54.74M | 104.30M | 190.65M | 195.91M | 248.49M | [{"date":"2019-12-31","value":22.03,"profit":true},{"date":"2020-12-31","value":41.97,"profit":true},{"date":"2021-12-31","value":76.72,"profit":true},{"date":"2022-12-31","value":78.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (54.74M) | (104.30M) | (173.41M) | (131.22M) | (109.15M) | [{"date":"2019-12-31","value":-5474300000,"profit":false},{"date":"2020-12-31","value":-10429600000,"profit":false},{"date":"2021-12-31","value":-17341300000,"profit":false},{"date":"2022-12-31","value":-13122000000,"profit":false},{"date":"2023-12-31","value":-10915400000,"profit":false}] |
Total Non-Operating Income/Expense | 4.44M | 2.26M | 72.24M | (22.97M) | (57.07M) | [{"date":"2019-12-31","value":6.15,"profit":true},{"date":"2020-12-31","value":3.12,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-31.8,"profit":false},{"date":"2023-12-31","value":-79,"profit":false}] |
Pre-Tax Income | (52.53M) | (103.26M) | (83.95M) | (142.07M) | (162.42M) | [{"date":"2019-12-31","value":-5253200000,"profit":false},{"date":"2020-12-31","value":-10326400000,"profit":false},{"date":"2021-12-31","value":-8395100000,"profit":false},{"date":"2022-12-31","value":-14207100000,"profit":false},{"date":"2023-12-31","value":-16242400000,"profit":false}] |
Income Taxes | 21.00K | 6.00K | 37.00K | (6.41M) | 991.00K | [{"date":"2019-12-31","value":2.12,"profit":true},{"date":"2020-12-31","value":0.61,"profit":true},{"date":"2021-12-31","value":3.73,"profit":true},{"date":"2022-12-31","value":-646.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (52.55M) | (103.27M) | (83.99M) | (135.66M) | (163.41M) | [{"date":"2019-12-31","value":-5255300000,"profit":false},{"date":"2020-12-31","value":-10327000000,"profit":false},{"date":"2021-12-31","value":-8398800000,"profit":false},{"date":"2022-12-31","value":-13566500000,"profit":false},{"date":"2023-12-31","value":-16341500000,"profit":false}] |
Income From Continuous Operations | (52.55M) | (103.27M) | (83.99M) | (135.66M) | (164.19M) | [{"date":"2019-12-31","value":-5255300000,"profit":false},{"date":"2020-12-31","value":-10327000000,"profit":false},{"date":"2021-12-31","value":-8398800000,"profit":false},{"date":"2022-12-31","value":-13566500000,"profit":false},{"date":"2023-12-31","value":-16418700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (52.55M) | (103.27M) | (83.99M) | (135.66M) | (163.41M) | [{"date":"2019-12-31","value":-5255300000,"profit":false},{"date":"2020-12-31","value":-10327000000,"profit":false},{"date":"2021-12-31","value":-8398800000,"profit":false},{"date":"2022-12-31","value":-13566500000,"profit":false},{"date":"2023-12-31","value":-16341500000,"profit":false}] |
EPS (Diluted) | (7.54) | (4.08) | (6.35) | (4.02) | (3.97) | [{"date":"2019-12-31","value":-753.53,"profit":false},{"date":"2020-12-31","value":-408,"profit":false},{"date":"2021-12-31","value":-635,"profit":false},{"date":"2022-12-31","value":-402,"profit":false},{"date":"2023-12-31","value":-397,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MIRM | |
---|---|
Cash Ratio | 2.46 |
Current Ratio | 3.34 |
Quick Ratio | 3.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MIRM | |
---|---|
ROA (LTM) | -9.10% |
ROE (LTM) | -39.84% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MIRM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.65 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.35 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MIRM | |
---|---|
Trailing PE | NM |
Forward PE | 61.35 |
P/S (TTM) | 6.63 |
P/B | 8.77 |
Price/FCF | 535 |
EV/R | 6.74 |
EV/Ebitda | NM |
Mirum Pharmaceuticals Inc (MIRM) share price today is $42.39
Yes, Indians can buy shares of Mirum Pharmaceuticals Inc (MIRM) on Vested. To buy Mirum Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MIRM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mirum Pharmaceuticals Inc (MIRM) via the Vested app. You can start investing in Mirum Pharmaceuticals Inc (MIRM) with a minimum investment of $1.
You can invest in shares of Mirum Pharmaceuticals Inc (MIRM) via Vested in three simple steps:
The 52-week high price of Mirum Pharmaceuticals Inc (MIRM) is $48.89. The 52-week low price of Mirum Pharmaceuticals Inc (MIRM) is $23.14.
The price-to-earnings (P/E) ratio of Mirum Pharmaceuticals Inc (MIRM) is
The price-to-book (P/B) ratio of Mirum Pharmaceuticals Inc (MIRM) is 8.77
The dividend yield of Mirum Pharmaceuticals Inc (MIRM) is 0.00%
The market capitalization of Mirum Pharmaceuticals Inc (MIRM) is $2.04B
The stock symbol (or ticker) of Mirum Pharmaceuticals Inc is MIRM